Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer
Ron Epelbaum(University of Bern), Gil Bar‐Sela(Emek Medical Center), B. Vizel(Rambam Health Care Campus)
Cited by 17
Related Papers
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
|Nature Medicine|2019|328
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279